CXCL10 and gastric cancer: The CXCL10/CXCR3 axis enhances GC cell invasion by stimulating MMP-2/9 secretion through the PI3K/AKT pathway, suggesting that a CXCR3 could be a candidate for targeted therapy for GC patients [132].